

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 August 2019 (15.08.2019)



(10) International Publication Number
WO 2019/157366 A8

(51) International Patent Classification:

A61K 38/17 (2006.01) C07K 14/705 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2019/017330

(22) International Filing Date:

08 February 2019 (08.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/628,161 08 February 2018 (08.02.2018) US
62/716,259 08 August 2018 (08.08.2018) US

(71) Applicant: **DRAGONFLY THERAPEUTICS, INC.**
[US/US]; 35 Gatehouse Drive, Waltham, MA 02451 (US).

(72) Inventors: **CHANG, Gregory, P.**; 143 Saunders Street, Medford, MA 02155 (US). **CHEUNG, Ann, F.**; 25 Morningside Lane, Lincoln, MA 01773 (US). **GRINBERG, Asya**; 37 Follen Road, Lexington, MA 02421 (US). **HANEY, William**; 61 Lincoln Road, Wayland, MA 01778 (US). **LUNDE, Bradley, M.**; 7 Lucent Drive, Lebanon, NH 03766 (US). **PRINZ, Bianka**; 7 Lucent Drive, Lebanon, NH 03766 (US).

(74) Agent: **ASHRAF, Shovon** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR




FIG. 14

(57) Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

17 September 2020 (17.09.2020)

(15) Information about Correction:

see Notice of 17 September 2020 (17.09.2020)